-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Friday's Intraday Session
Share
Listen to the news

Gainers

  • PRF Technologies (NASDAQ:PRFX) stock rose 231.0% to $4.54 during Friday's regular session. The company's market cap stands at $1.1 million.
  • CDT Equity (NASDAQ:CDT) stock increased by 120.35% to $2.09. The company's market cap stands at $4.6 million.
  • Replimune Group (NASDAQ:REPL) shares rose 80.55% to $8.45. The company's market cap stands at $367.1 million.
  • Clearmind Medicine (NASDAQ:CMND) shares moved upwards by 44.9% to $3.55. The company's market cap stands at $2.4 million.
  • Scilex Holding (NASDAQ:SCLX) stock moved upwards by 31.76% to $9.5. The company's market cap stands at $50.7 million.
  • C4 Therapeutics (NASDAQ:CCCC) stock rose 20.21% to $4.4. The company's market cap stands at $404.6 million.

Losers

  • Aditxt (NASDAQ:ADTX) shares declined by 27.4% to $0.12 during Friday's regular session.
  • Aethlon Medical (NASDAQ:AEMD) shares declined by 24.49% to $2.22. The company's market cap stands at $4.6 million.
  • Co-Diagnostics (NASDAQ:CODX) shares decreased by 24.04% to $8.5. The market value of their outstanding shares is at $40.9 million.
  • Akari Therapeutics (NASDAQ:AKTX) shares decreased by 22.87% to $17.01. The company's market cap stands at $25.2 million.
  • Agape ATP (NASDAQ:ATPC) stock fell 19.61% to $4.88. The market value of their outstanding shares is at $6.0 million.
  • SciSparc (NASDAQ:SPRC) stock declined by 17.07% to $8.75. The market value of their outstanding shares is at $5.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending